A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bio-equivalence of a New Tapentadol Extended-Release (TRF) 50-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 50-mg Tablet Under Fasted Conditions in Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain; Musculoskeletal pain; Pain
- Focus Pharmacokinetics
- 24 Jul 2013 New trial record